Related Experiment Video
Updated: Apr 11, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
[Metformin can reduce the risk of colorectal cancer]
Tina Fransgård1, Ismail Gögenur
1Kirurgisk Forskningsenhed, Kirurgisk Afdeling, Køge Sygehus, Lykkebækvej 1, 4600 Køge. tifer@regionsjaelland.dk.
Abstract:
Diabetes mellitus (DM) is an established, independent risk factor for colorectal cancer (CRC). Metformin is the first drug of choice for type 2 DM. Several studies have shown a decreased risk of developing CRC in patients with metformin-treated DM, compared with patients with diabetes not treated with metformin. An increased overall survival and CRC-specific survival in patients with CRC and metformin-treated DM has still not been substantially proven. Further studies are needed before a conclusion can be made whether metformin should be used in the treatment of CRC.
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Cancer Prevention
Some...
Cancer Prevention
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Dipeptidyl Peptidase 4 Inhibitors

